Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 33

1.

Increasing incidence and survival of corpus uteri cancer in Estonia over the past two decades.

Ojamaa K, Veerus P, Baburin A, Everaus H, Innos K.

Cancer Epidemiol. 2019 Jul 18;62:101566. doi: 10.1016/j.canep.2019.101566. [Epub ahead of print]

PMID:
31326850
2.

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.

Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA.

Haematologica. 2019 Jul 11. pii: haematol.2018.214882. doi: 10.3324/haematol.2018.214882. [Epub ahead of print]

3.

Trends in cervical cancer incidence and survival in Estonia from 1995 to 2014.

Ojamaa K, Innos K, Baburin A, Everaus H, Veerus P.

BMC Cancer. 2018 Nov 7;18(1):1075. doi: 10.1186/s12885-018-5006-1.

4.

Established Human Cell Lines as Models to Study Anti-leukemic Effects of Flavonoids.

Sak K, Everaus H.

Curr Genomics. 2017 Feb;18(1):3-26. doi: 10.2174/1389202917666160803165447.

5.

Time Trends in Ovarian Cancer Survival in Estonia by Age and Stage.

Ojamaa K, Veerus P, Baburin A, Everaus H, Innos K.

Int J Gynecol Cancer. 2017 Jan;27(1):44-49. doi: 10.1097/IGC.0000000000000858.

PMID:
27870707
6.

Treatment and outcome of 2904 CML patients from the EUTOS population-based registry.

Hoffmann VS, Baccarani M, Hasford J, Castagnetti F, Di Raimondo F, Casado LF, Turkina A, Zackova D, Ossenkoppele G, Zaritskey A, Höglund M, Simonsson B, Indrak K, Sninska Z, Sacha T, Clark R, Bogdanovic A, Hellmann A, Griskevicius L, Schubert-Fritschle G, Sertic D, Guilhot J, Lejniece S, Zupan I, Burgstaller S, Koskenvesa P, Everaus H, Costeas P, Lindoerfer D, Rosti G, Saussele S, Hochhaus A, Hehlmann R.

Leukemia. 2017 Mar;31(3):593-601. doi: 10.1038/leu.2016.246. Epub 2016 Aug 29.

PMID:
27568522
7.

Acute de novo Leukemia in Estonia and Western Sweden 1982-2006: Positive Trend in the Survival of Acute Leukemia over 25 Years.

Hulegårdh E, Punab M, Holmberg E, Palk K, Laane E, Everaus H, Wennström L, Stockelberg D.

Acta Haematol. 2016;136(3):167-73. doi: 10.1159/000446525. Epub 2016 Aug 19.

PMID:
27537981
8.

Potentiation of luteolin cytotoxicity by flavonols fisetin and quercetin in human chronic lymphocytic leukemia cell lines.

Sak K, Kasemaa K, Everaus H.

Food Funct. 2016 Sep 14;7(9):3815-24. doi: 10.1039/c6fo00583g. Epub 2016 Aug 4.

PMID:
27489195
10.

Multi-Target Cytotoxic Actions of Flavonoids in Blood Cancer Cells.

Sak K, Everaus H.

Asian Pac J Cancer Prev. 2015;16(12):4843-7. Review.

11.

Chemomodulating Effects of Flavonoids in Human Leukemia Cells.

Sak K, Everaus H.

Anticancer Agents Med Chem. 2015;15(9):1112-26. Review.

PMID:
25986578
12.

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries.

Hoffmann VS, Baccarani M, Hasford J, Lindoerfer D, Burgstaller S, Sertic D, Costeas P, Mayer J, Indrak K, Everaus H, Koskenvesa P, Guilhot J, Schubert-Fritschle G, Castagnetti F, Di Raimondo F, Lejniece S, Griskevicius L, Thielen N, Sacha T, Hellmann A, Turkina AG, Zaritskey A, Bogdanovic A, Sninska Z, Zupan I, Steegmann JL, Simonsson B, Clark RE, Covelli A, Guidi G, Hehlmann R.

Leukemia. 2015 Jun;29(6):1336-43. doi: 10.1038/leu.2015.73. Epub 2015 Mar 18.

PMID:
25783795
13.

Role of flavonoids in future anticancer therapy by eliminating the cancer stem cells.

Sak K, Everaus H.

Curr Stem Cell Res Ther. 2015;10(3):271-82. Review.

PMID:
25429700
14.

A mathematical model of natural killer cell activity.

Scherbakova A, Lust H, Everaus H, Aints A.

Cytometry A. 2013 Jun;83(6):585-91. doi: 10.1002/cyto.a.22283. Epub 2013 Apr 18.

15.

Sequential population-based studies over 25 years on the incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1982-2006: a survey of patients aged ≥65 years.

Punab M, Palk K, Varik M, Laane E, Everaus H, Holmberg E, Hulegårdh E, Wennström L, Safai-Kutti S, Stockelberg D, Kutti J.

Med Oncol. 2013 Mar;30(1):487. doi: 10.1007/s12032-013-0487-x. Epub 2013 Feb 9.

PMID:
23397082
16.

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients.

Raber-Durlacher JE, von Bültzingslöwen I, Logan RM, Bowen J, Al-Azri AR, Everaus H, Gerber E, Gomez JG, Pettersson BG, Soga Y, Spijkervet FK, Tissing WJ, Epstein JB, Elad S, Lalla RV; Mucositis Study Group of the Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology (MASCC/ISOO).

Support Care Cancer. 2013 Jan;21(1):343-55. doi: 10.1007/s00520-012-1594-5. Epub 2012 Sep 18. Review.

PMID:
22987094
17.

The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997-2001: a survey of patients aged 16-64 years.

Wennström L, Safai-Kutti S, Stockelberg D, Holmberg E, Palk K, Varik M, Viigimaa I, Vaht K, Luik E, Everaus H, Kutti J.

Acta Haematol. 2011;126(3):176-85. doi: 10.1159/000329526. Epub 2011 Aug 13.

PMID:
21846971
18.

PTPN22 gene regulates natural killer cell proliferation during in vitro expansion.

Douroudis K, Shcherbakova A, Everaus H, Aints A.

Tissue Antigens. 2010 Oct;76(4):315-8. doi: 10.1111/j.1399-0039.2010.01512.x.

PMID:
20522204
19.

The incidence and survival of acute de novo leukemias in Estonia and in a well-defined region of western Sweden during 1997-2001: a survey of patients aged >or=65 years.

Palk K, Luik E, Varik M, Viigimaa I, Vaht K, Everaus H, Wennström L, Stockelberg D, Safai-Kutti S, Holmberg E, Kutti J.

Cancer Epidemiol. 2010 Feb;34(1):24-8. doi: 10.1016/j.canep.2009.12.004. Epub 2010 Jan 13.

PMID:
20071253
20.

Changes in the natural history of renal cancer: comparison of Estonian data from the periods 1986-1988 and 1996-1998.

Padrik P, Kirsimägi U, Everaus H.

Int Urol Nephrol. 2007;39(1):35-41. Epub 2006 Oct 25.

PMID:
17063372
21.
22.

Flow cytometric immunophenotyping including Bcl-2 detection on fine needle aspirates in the diagnosis of reactive lymphadenopathy and non-Hodgkin's lymphoma.

Laane E, Tani E, Björklund E, Elmberger G, Everaus H, Skoog L, Porwit-MacDonald A.

Cytometry B Clin Cytom. 2005 Mar;64(1):34-42.

23.

The incidence and survival of acute de novo leukaemias in Estonia and in a well defined region of Western Sweden during 1982-1996: a survey of patients aged 16-64 years.

Wennström L, Juntikka EL, Safai-Kutti S, Stockelberg D, Holmberg E, Luik E, Everaus H, Palk K, Varik M, Aareleid T, Kutti J.

Leuk Lymphoma. 2004 May;45(5):915-21.

PMID:
15291349
24.

The incidence and survival of acute de novo leukaemias in Estonia and in a well-defined region of western Sweden during 1982-1996: a survey of patients aged > or =65 years.

Luik E, Palk K, Everaus H, Varik M, Aareleid T, Wennström L, Juntikka EL, Safai-Kutti S, Stockelberg D, Holmberg E, Kutti J.

J Intern Med. 2004 Jul;256(1):79-85.

25.

Nongenomic effects of 17beta-estradiol--diversity of membrane binding sites.

Sak K, Everaus H.

J Steroid Biochem Mol Biol. 2004 Apr;88(4-5):323-35. Review.

PMID:
15145442
26.

Involvement of P2Y receptors in the differentiation of haematopoietic cells.

Sak K, Boeynaems JM, Everaus H.

J Leukoc Biol. 2003 Apr;73(4):442-7. Review.

PMID:
12660218
27.

Some aspects of morphological and dysplastic changes of the bone marrow in malignant lymphoma.

Jakovleva K, Everaus H.

Acta Haematol. 1998 Dec;100(3):142-6.

PMID:
9858791
28.

Organizational changes in Estonia.

Everaus H.

Vox Sang. 1998;74 Suppl 2:531-3. Review.

PMID:
9704495
29.

Active and indolent chronic lymphocytic leukaemia--immune and hormonal peculiarities.

Everaus H, Luik E, Lehtmaa J.

Cancer Immunol Immunother. 1997 Oct;45(2):109-14.

PMID:
9390202
30.

Possible imbalance of the immuno-hormonal axis in multiple myeloma.

Everaus H, Hein M, Zilmer K.

Leuk Lymphoma. 1993 Nov;11(5-6):453-8.

PMID:
8124218
31.

Sex hormones and immune dysregulation in multiple myeloma.

Everaus H, Lehtmaa J.

Cancer Immunol Immunother. 1993;36(3):205-9.

PMID:
8439982
32.

Hormones and immune responsiveness in chronic lymphocytic leukemia.

Everaus H.

Leuk Lymphoma. 1992 Dec;8(6):483-9.

PMID:
1338427
33.

Immune and hormonal changes in early-stage chronic lymphocytic leukemia patients.

Everaus H, Lehtmaa J, Luik E, Kŏdar H.

Ann Hematol. 1992 Nov;65(5):219-23.

PMID:
1457579

Supplemental Content

Loading ...
Support Center